CYP19A1 knockdown boosted tumor-infiltrating CD8+ T cells and enhanced GzmB and IFNγ production, indicative of CD8+ T cells-elicited adaptive immunity against colon cancer, which were amplyfied in combination therapy (Fig. 9I). This evidence concerns the gene CD8A and malignant colon neoplasm.